Osteomalacia and osteoporosis both weaken bones and raise fracture risk, but they do so through fundamentally different mechanisms. Osteoporosis means you have less bone overall; osteomalacia means the bone you have isn’t properly hardened. That distinction sounds simple, but it creates real problems in the clinic because the two conditions can look alike on standard screening tests and sometimes even coexist in the same person.
The Core Difference Between the Two
Healthy bone is a composite material: a protein scaffold (mainly collagen) onto which mineral crystals are deposited. Think of it like reinforced concrete, where steel rebar provides flexibility and poured cement provides hardness. In osteoporosis, the body removes more bone than it rebuilds, so you end up with less of both the scaffold and the mineral. The architecture thins out, leaving bones that are structurally weaker and more likely to snap under stress. In osteomalacia, the scaffold gets built at a normal or even increased rate, but the mineral never fully deposits onto it. The result is bone that is softer and more flexible than it should be, which can bend under load or fracture in unusual ways.
This distinction was first described in the 19th century by the German pathologist Pommer, who examined cadaveric bones and recognized that osteomalacia left behind excess unmineralized bone matrix (called osteoid), while osteoporosis simply produced less bone volume overall. That separation still holds today as the defining line between the two diseases.
How Symptoms Overlap and Where They Diverge
Both conditions can cause fractures, which is one reason they’re confused. But the way people feel before fractures happen tends to differ. Osteoporosis is often called a “silent disease” because bone density drops without producing pain or obvious symptoms until a fracture occurs, typically in the hip, spine, or wrist.
Osteomalacia, by contrast, usually announces itself. The hallmark symptoms are diffuse bone pain and tenderness, proximal muscle weakness (especially in the thighs), and a characteristic waddling gait caused by the inability to lift the legs properly off the ground. Muscle involvement is common, affecting anywhere from about half to nearly all patients depending on how severe and prolonged the vitamin D deficiency is.1JBMR Plus. Osteomalacia and Vitamin D Status: A Clinical Update 2020 Because incompletely mineralized bone is more flexible, long bones in the legs can actually bow over time. And osteomalacia produces a distinctive radiographic sign: pseudofractures, also called Looser’s zones, which are bands of unmineralized bone that look like cracks on an X-ray and are almost always diagnostic in the right clinical setting.2JBMR Plus. Osteomalacia and Vitamin D Status: A Clinical Update 2020
People with osteoporosis don’t typically have the diffuse aching or the muscle weakness. Their fractures tend to occur with falls or minimal trauma, and spinal compression fractures can happen silently, sometimes only noticed when someone loses height over time. That said, the symptom overlap is real enough that you can’t reliably distinguish the two on clinical presentation alone.
Different Causes, Different Pathways
The causes of each condition reflect the underlying mechanism. Osteoporosis is most often driven by hormonal changes. In women, estrogen deficiency after menopause accelerates the activity of bone-resorbing cells (osteoclasts), tipping the balance so that bone is broken down faster than it’s rebuilt.3PubMed Central. HIF1α is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis Estrogen normally keeps those resorbing cells in check by promoting signals that restrain osteoclast formation. When estrogen drops, those restraints lift, and a cascade of inflammatory signals speeds up bone loss.4PubMed Central. Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover Aging itself, low physical activity, smoking, and excessive alcohol also contribute.
Osteomalacia, on the other hand, is almost always a problem of vitamin D or phosphate supply. Vitamin D is essential for the gut to absorb calcium and phosphate from food, and those minerals are what harden bone. The most common cause worldwide is simply not getting enough vitamin D, whether from sunlight, diet, or both. But osteomalacia can also arise from conditions that waste phosphate through the kidneys, or from diseases that prevent the gut from absorbing nutrients properly (like celiac disease or inflammatory bowel disease). In rare cases, tumors can secrete a hormone called FGF23 that drives phosphate out through the kidneys, causing a form known as tumor-induced osteomalacia.5Journal of the Endocrine Society. PSAT223 A Delayed Diagnosis of Oncogenic Osteomalacia Presenting with Bone Pain, Muscle Weakness and Elevated Alkaline Phosphatase
Why a Bone Density Scan Can Miss the Difference
This is where the practical confusion gets dangerous. The standard screening test for osteoporosis is a DXA scan, which measures bone mineral density. Both osteoporosis and osteomalacia can produce low DXA scores, because both conditions reduce the amount of mineral in a given volume of bone, just for different reasons. Osteoporosis has less bone tissue overall; osteomalacia has bone tissue that’s undermineralized. The DXA machine can’t tell the difference. It simply reports a low density number either way.
A bone density test cannot distinguish between osteoporosis and other metabolic bone disorders like osteomalacia, and it reveals nothing about the microarchitecture of bone, mineralization quality, cellular activity, or remodeling dynamics.6Bone Reports. Bone histomorphometry in the evaluation of osteomalacia This means a person with osteomalacia can receive an osteoporosis diagnosis based on their DXA results, and then be started on osteoporosis medications that are completely wrong for their actual condition.
To definitively confirm osteomalacia, clinicians sometimes rely on bone biopsy with histomorphometry, a technique that involves taking a tiny sample of bone and examining it under a microscope to measure the thickness of unmineralized osteoid seams. In osteomalacia, these seams are abnormally wide, which can be reliably detected using various measurement methods.7PubMed. Equivalency of various methods for estimating osteoid seam width Blood tests for vitamin D, calcium, phosphate, alkaline phosphatase, and parathyroid hormone help as well, but the biopsy remains the gold standard when the diagnosis is uncertain.
Why Getting the Diagnosis Right Matters
The treatment for each condition is not just different but potentially opposed, which makes misdiagnosis a genuine safety concern. Osteoporosis is commonly treated with bisphosphonates, a class of drugs that slow down bone resorption by inhibiting osteoclast activity. That makes sense when the core problem is too much bone being broken down. But if the real problem is osteomalacia, bisphosphonates can make things worse.
Bisphosphonates work by suppressing the normal turnover cycle. In osteomalacia, where the bone that exists is already poorly mineralized, shutting down the turnover process freezes the skeleton’s ability to repair itself. A case report of a patient with undiagnosed Fanconi syndrome described exactly this scenario: zoledronate (a potent bisphosphonate) given for what was assumed to be osteoporosis instead “froze” cellular activity on top of pre-existing osteomalacia, severely impairing bone self-repair and precipitating an increased fracture rate.8JBMR Plus. Bisphosphonate Induced Deterioration of Osteomalacia in Undiagnosed Adult Fanconi Syndrome The authors emphasized that inhibitors of bone resorption must not be given to people with osteomalacia, because in addition to biochemical changes, marked clinical deterioration can follow.
Osteomalacia treatment, by contrast, focuses on replacing what’s missing. For vitamin D deficiency, high-dose vitamin D supplementation along with calcium is usually sufficient and can be remarkably effective. For phosphate-wasting forms, phosphate supplements and sometimes activated vitamin D are used. The bone can remineralize once the raw materials are available again, which is quite different from osteoporosis, where lost bone architecture doesn’t simply grow back.
When Both Conditions Exist at the Same Time
Osteomalacia and osteoporosis aren’t mutually exclusive. They can coexist, especially in settings where nutritional deficiencies and age-related bone loss converge. One well-documented example comes from bariatric surgery patients, particularly those who have had malabsorptive procedures. A study of 46 patients evaluated after bariatric surgery found that about 9% met criteria for osteomalacia, and all of those patients also had densitometric osteoporosis, with most developing fractures or pseudofractures after their surgery.9PubMed. Bariatric surgery: Think about osteomalacia too These patients showed elevated parathyroid hormone, low vitamin D, and high alkaline phosphatase, signs that mineralization was impaired on top of reduced bone mass.
This overlap matters because treating only one condition while ignoring the other leaves the patient vulnerable. Giving someone bisphosphonates for their osteoporosis when they also have unrecognized osteomalacia carries the risks described above. Conversely, correcting vitamin D deficiency alone won’t restore the bone volume that’s already been lost to osteoporosis. In dual cases, clinicians need to address the mineralization defect first, then consider anti-resorptive therapy once the bone is properly mineralized.
The Kidney Connection
Chronic kidney disease creates a particularly tangled version of this overlap. The kidneys are responsible for converting vitamin D into its active form, and when kidney function declines, that conversion drops. The result is a cascade: less active vitamin D means less calcium absorption from the gut, which triggers the parathyroid glands to ramp up parathyroid hormone production, which in turn pulls calcium out of bone. This condition, called renal osteodystrophy, is defined by the presence of osteomalacia combined with the hyperparathyroidism that results from failing kidneys.10PubMed. Osteomalacia and Renal Osteodystrophy
People with advanced kidney disease can therefore have undermineralized bone and accelerated bone loss simultaneously, driven by the same upstream cause. Their DXA scans will show low bone density, but the treatment is neither standard osteoporosis therapy nor simple vitamin D supplementation. It requires managing the kidney disease itself, using activated forms of vitamin D that bypass the kidney’s conversion step, controlling phosphate levels, and sometimes addressing the overactive parathyroid glands directly. This is one of the clearest examples of why understanding the difference between osteomalacia and osteoporosis isn’t academic; it changes the entire treatment approach.
Drugs That Can Cause Each Condition
Certain medications can trigger either osteoporosis or osteomalacia, but the culprits for each tend to be different, which further underscores the mechanistic distinction. Corticosteroids have widespread effects on calcium metabolism, decreasing bone formation while enhancing resorption, leading to accelerated osteoporosis. Drugs like aluminum-containing antacids and anticonvulsants, on the other hand, impair mineralization and can lead to osteomalacia.11PubMed. Drug-induced disorders of bone metabolism. Incidence, management and avoidance
An analysis of French and Spanish pharmacovigilance databases confirmed these patterns on a larger scale. Corticosteroids accounted for roughly half of all drug-induced osteoporosis reports in France, followed by antivirals and antacids. For drug-induced osteomalacia, the picture was quite different: antiretroviral drugs (used to treat HIV) accounted for the majority of reports, followed by antiepileptic drugs.12PubMed. Drug-induced osteoporosis/osteomalacia: analysis in the French and Spanish pharmacovigilance databases Anticonvulsants showed up on both lists, likely because some of these drugs accelerate the breakdown of vitamin D in the liver, reducing the active form available for mineralization, while also having direct effects on bone cells.
For anyone on long-term corticosteroids, anticonvulsants, or antiretroviral therapy, bone health monitoring should be on the table. But the type of monitoring matters. A DXA scan alone might flag a problem without revealing its nature. If the medication is one that’s known to impair mineralization, clinicians should check vitamin D and phosphate levels rather than reflexively prescribing a bisphosphonate.
How Osteomalacia Affects Movement
One of the most distinctive features of osteomalacia that sets it apart from osteoporosis in daily life is its effect on muscles and mobility. The proximal muscle weakness that accompanies osteomalacia, particularly in the thighs and hips, creates a characteristic gait pattern. Patients have difficulty rising from a seated position, climbing stairs, or lifting their legs, and they may develop a waddling walk. A case report documented this pattern in a patient whose osteomalacia turned out to be caused by celiac disease. The patient presented with proximal muscle weakness and waddling gait as the primary symptoms, and the underlying cause was traced through laboratory findings to malabsorption and severe vitamin D deficiency.13Osteoporosis International. Proximal muscle weakness as a result of osteomalacia associated with celiac disease: a case report
Osteoporosis doesn’t produce this kind of muscle involvement. A person with osteoporosis may be at increased fall risk due to age-related muscle loss (sarcopenia), poor balance, or other age-associated factors, but those aren’t caused by the osteoporosis itself. The muscle weakness in osteomalacia, by contrast, is a direct consequence of the vitamin D or phosphate deficiency that’s also impairing bone mineralization. Correcting the deficiency typically resolves the weakness alongside the bone problem, which is a useful clinical clue: if your bone pain came with muscle weakness and improved dramatically with vitamin D, osteomalacia was likely the culprit.
Blood Tests and Lab Clues
While a bone biopsy is the definitive way to diagnose osteomalacia, blood work often provides strong enough clues to guide treatment without one. Osteomalacia typically shows some combination of low serum calcium, low phosphate, elevated alkaline phosphatase (because the bone-forming cells are working hard even though mineralization is failing), elevated parathyroid hormone, and low vitamin D levels. Osteoporosis, by contrast, usually presents with entirely normal blood chemistry. Calcium, phosphate, and vitamin D levels can all be in the normal range while bone density is steadily declining, because the problem is one of architecture and remodeling balance, not mineral supply.
This distinction makes blood work a useful first step when someone shows up with a low DXA score. If the basic metabolic panel and vitamin D level come back normal, osteoporosis is the likelier diagnosis. If alkaline phosphatase is elevated and vitamin D is low, osteomalacia moves to the front of the list. In the bariatric surgery study mentioned earlier, all four patients who met osteomalacia criteria had elevated alkaline phosphatase and parathyroid hormone alongside low vitamin D, a biochemical pattern that should have prompted clinicians to think beyond osteoporosis.14PubMed. Bariatric surgery: Think about osteomalacia too
Who Is at Highest Risk for Each
The risk profiles for the two conditions only partially overlap. Osteoporosis disproportionately affects postmenopausal women because of estrogen’s role in restraining bone resorption.15PubMed. Estrogen and bone: osteoclasts take center stage Older men are also at risk, especially with age-related declines in testosterone and physical activity, but the prevalence is lower than in women. Family history, low body weight, smoking, and chronic glucocorticoid use all increase risk.
Osteomalacia risk, meanwhile, tracks with anything that disrupts vitamin D or phosphate metabolism. People living at high latitudes with limited sun exposure, those with dark skin (which reduces vitamin D synthesis), institutionalized older adults who rarely go outside, people with malabsorptive gut conditions, individuals on anticonvulsants or certain antiretrovirals, patients with kidney disease, and anyone who has had malabsorptive bariatric surgery are all at elevated risk. Importantly, osteomalacia can strike at any age, including young adults and even children (where the equivalent condition in growing skeletons is called rickets). Osteoporosis, while it can occur in younger people due to medications or other secondary causes, overwhelmingly clusters in the older population.
This difference in risk populations means the two diseases sometimes get missed in opposite directions. A 35-year-old woman with diffuse bone pain and fatigue might not be screened for either condition because she’s “too young for osteoporosis,” when in fact she has osteomalacia from celiac disease. A 70-year-old woman put on bisphosphonates for a low DXA score might actually have osteomalacia from severe vitamin D deficiency that nobody checked because osteoporosis seemed like the obvious answer. The practical lesson is straightforward: check vitamin D and phosphate levels before starting osteoporosis treatment, especially when the clinical picture includes bone pain or muscle weakness.